A team of cutting-edge researchers based in Dundee, who recently discovered a revolutionary drug to treat skin cancer, have been awarded nearly £30 million in funding.
The Courier, who reported on the story, state that this substantial financial boost will enable the group to continue their pioneering work, aiming to make further breakthroughs in treating some of the most challenging and currently incurable diseases.
The funding will support a 200-strong research community at the University of Dundee, allowing them to deepen their investigations into the mechanisms of diseases and explore potential treatments for conditions such as Motor Neurone Disease (MND) and Crohn’s disease.
Central to their work is understanding how signals are transmitted within the body’s cells, a key area of research that holds the potential to unlock new therapeutic approaches.
The research unit, known as the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (PPU) at the University of Dundee, has already played a crucial role in the development and approval of over 40 drugs currently used in clinical settings.
These treatments are now widely employed to improve patient outcomes in various conditions. Their success has also attracted nearly £60 million in private investment, further cementing the unit’s reputation as a global leader in medical research.
With this new funding, the Dundee team aims to accelerate their research efforts, continuing their vital work to uncover new therapies for some of the most debilitating conditions faced by patients today.
The cutting-edge approach aims to advance scientific understanding and also offers hope for future medical breakthroughs that could transform lives.
Sources and further reading
Comments